louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04887441: Allergology: Information, Data and Knowledge Organization
Official title: Allergology: Information, Data and Knowledge Organization
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Food Allergy
Peanut Allergy
Keywords: Food allergy
peanuts
Oral Immunotherapy
efficacy
safety
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
Collaborators: name: LERASS-CERIC Université Paul Valéry Montpellier 3 Motpellier
name: Occitanie Region
First posted: 2021-05-14
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthcare professional of the Allergy Unit of the University Hospital of Montpellier (France)

Brief summary: Digital technology is essential in the field of health, via connected objects, the medical Internet or even telemedicine; and the info-communication practices (ways of getting information and communicating) of the actors go through digital devices. In addition, at present, the mass of activity documents to be managed in healthcare establishments and an abundant supply of documentary resources in health, available on the Internet, lead to infobesity, information pollution, and work overload. These phenomena lead to an increase in the time spent searching for relevant information and even to the burnout of healthcare professionals. A contextualization of the information communication systems through which the practices of health professionals pass therefore seems necessary so that the tools for managing, extracting and organizing knowledge can support these actors in their work.

In the field of allergies, there are many players, and the information that is useful to them is abundant and heterogeneous. This study is based on the hypothesis that a knowledge organization model, developed from existing practices, could make it possible to obtain satisfactory results when searching for information, and be integrated into the daily practices of actors by linking up with other already existing systems and tools.


Eligibility criteria: Inclusion criteria:

* Professionals from the Allergy Unit (doctors, interns, paramedics, study coordinators), in total around 20-30 people.
* Observations will be conducted during their team meetings and will not impact their workflow.
* Subjects publishing information on allergy on public web sites

Exclusion criteria:

* Professional not willing to participate to the research.
* Users publishing information on private web sites or forums.

Primary outcomes:
measure: Evaluation of the ontology model
timeFrame: 24 months
Secondary outcomes:
measure: Assessment and validation of the model
timeFrame: 18 months
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Davide CAIMMI
role: STUDY_DIRECTOR
References:
Clinical trial NCT05411341: Comparison of Two Different Optical Biometric Systems
Official title: Assessment of Two Different Optical Biometric Systems, Based on Different Optical Technologies in Patients With Cataract or Presbyopia
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cataract
Presbyopia
Ocular Biometry
Intraocular Lens
Keywords: cataract
presbyopia
argos
iol master 500
optical biometric system
Lead sponsor: Democritus University of Thrace
Sponsor class: OTHER
First posted: 2022-06-09
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients with cataract and/or presbyopia.

Brief summary: Primary objective of this study is to evaluate and compare the measurements of two different optical biometrics systems in patients who will undergo cataract surgery or presbyopia surgery using intraocular lenses (IOL-PC).

Detailed description: This is a prospective study including patients visiting the outpatient Ophthalmology clinic of the University General Hospital of Alexandroupolis, who suffer from diagnosed cataract or presbyopia and are going to undergo implantation of intraocular lenses surgery. The patients will be fully informed about the procedure and the purpose of the study and a written informed consent will be provided by all participants. They will then undergo an ocular biometry examination using two optical biometric systems, Argos (Alcon Laboratories, Inc.) and IOLMaster 500 (Carl Zeiss Meditec AG). IOL Master 500 (Carl Zeiss Meditec AG) is a non-invasive optical biometer that uses partial coherence interferometry (PCI) with a wavelength of 780 nm to measure the AL of the eye. Argos (Alcon Laboratories, Inc.) is a novel non-invasive optical biometer that uses swept source optical coherence tomography (SS-OCT) with a wavelength of 1050 nm. The measurements of the two systems that will be compared are the axial length, the keratometry values, the anterior chamber depth (ACD), the horizontal corneal diameter (white to white \[WTW\]) and the lens power in diopters (D).

Eligibility criteria: Inclusion Criteria:

* Patients with cataract and/or presbyopia who will undergo intraocular lens implantation.

Exclusion Criteria:

* Dense cataract that does not allow measurements to be taken with an optical biometrics system.

Primary outcomes:
measure: Axial length
timeFrame: 1 week
measure: Keratometry values
timeFrame: 1 week
measure: Lens power (D)
timeFrame: 1 week
Secondary outcomes:
measure: Anterior chamber depth (ACD)
timeFrame: 1 week
measure: Horizontal corneal diameter (white to white [WTW])
timeFrame: 1 week
Other outcomes:
Locations:
city: Alexandroupolis
country: Greece
facility: Department of Ophthalmology, University Hospital of Alexandroupolis
state: Evros
Study officials:
affiliation: Department of Ophthalmology, University Hospital of Alexandroupolis, Alexandroupolis, Greece
name: Georgios Labiris, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06110741: Evaluation of the Consequences of Poly Vaccination on Innate Immunity : Applications to a Military Population
Official title: VaxInnate : Evaluation of the Consequences of Poly Vaccination on Innate Immunity : Applications to a Military Population
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Vaccine Breakthrough Infections
Lead sponsor: Direction Centrale du Service de Santé des Armées
Sponsor class: OTHER
First posted: 2023-11-01
Enrollment: 410
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population is composed by healthy subjects which have to receive a vaccine update in order to be deployed

Brief summary: In this study, the poly vaccination of military personnel prior to deployment will be analyzed in terms of central, peripheral and long-lasting changes in innate immunity.

Analysis of monocyte immune training induced by vaccination will provide a better understanding of the indirect effects of vaccination and their persistence over time.


Eligibility criteria: Inclusion Criteria:

* french military personnel
* \>18yo
* overseas deployment scheduled between 30 and 60 days after vaccination session
* adult
* able to give consent

Exclusion Criteria:

* unrectified military personnel
* having received a live vaccine within 6 months prior to inclusion
* having received an attenuated vaccine within 3 months prior to inclusion
* pregnancy or breastfeeding
* vaccine contraindication
* major incapacity

Primary outcomes:
measure: Monocytes' functional reprogramming
timeFrame: 11 months
Secondary outcomes:
measure: Identify immune signatures
timeFrame: 11 months
measure: Time persistence
timeFrame: 11 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02583841: "Effect of Scaling and Root Planing on Liver Function Test (Alanine Aminotransferase and Aspartate Aminotransferase) in Systemically Healthy - Chronic Periodontitis Subjects: a Clinical Trial."
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Chronic Periodontitis (CP) Subjects.
Lead sponsor: Tatyasaheb Kore Dental College
Sponsor class: OTHER
First posted: 2015-10-22
Enrollment: 50
Sex: ALL
Minimum age (years): 35
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Aim:

To evaluate effect of non- surgical periodontal therapy on liver function in systemically healthy chronic periodontitis (CP) subjects.

Materials and methods:

The study is non surgical interventional trial, includes 50 CP subjects in the age group of 35- 60 years selected from the OPD (Out Patient Department) of department of periodontology Tatyasaheb Kore Dental College and Research center (TKDC and RC), Kolhapur. CP subjects were equally divided into test group and control group. Liver function test- aspartate aminotransferase (AST), alanine aminotransferase (ALT) were checked at baseline and at 1 month after treatment. Clinical examination includes plaque index, gingival index, sulcus bleeding index, probing depth, clinical attachment loss.


Eligibility criteria: Inclusion Criteria:

1. Subjects with CP (moderate and severe) as per Centers for disease control and prevention (CDC) criteria 2007.
2. Patients without any known systemic diseases

   -

Exclusion Criteria:

1. Patients who have taken anti-inflammatory/antibiotic/antioxidant within 3 months of beginning of study.
2. Subjects who have undergone periodontal treatment within six months of inception of study.
3. Smokers, tobacco habits in any form and alcoholics.
4. Pregnant and lactating women.

   -

Primary outcomes:
measure: Alanine aminotransferase
timeFrame: 1month
measure: Aspartate aminotransferase
timeFrame: 1 month
Secondary outcomes:
measure: plaque index
timeFrame: 1month
measure: gingival index
timeFrame: 1 month
measure: sulcus bleeding index
timeFrame: 1month
measure: probing depth
timeFrame: 1month
measure: Clinical attachment loss
timeFrame: 1 month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03487341: Placental Cord Drainage After Vaginal Delivery
Official title: Placental Cord Drainage After Vaginal Delivery: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Blood Loss
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2018-04-04
Enrollment: 600
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Placental Cord Drainage after Vaginal Delivery A randomized clinical trial


Eligibility criteria: Inclusion Criteria:

* Singleton pregnancy.
* Pregnancy with vertex presentation.
* Gestational age37 up to 42 weeks
* Patient expected to have spontaneous vaginal delivery.
* Maternal age 18 years old or more.

Exclusion Criteria:

* Previous history of Postpartum hemorrhage.
* Antepartum hemorrhage
* Multiple pregnancies
* Instrumental deliveries
* Coagulation disorders
* Over distended uterus (hydramnios, large fetus).
* Patient with extensive extended vaginal or cervical tear.
* Rupture uterus.
* Secondary arrest of cervical dilatation.
* Persistent occipito-posterior.
* Deep transverse arrest of fetal head.

Primary outcomes:
measure: blood loss
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University Maternity Hospital
Study officials:
References:
Clinical trial NCT01025934: Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
Official title: Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Proliferative Diabetic Retinopathy
Lead sponsor: University of Campania Luigi Vanvitelli
Sponsor class: OTHER
Collaborators: name: Napoli CTO Hospital
First posted: 2009-12-04
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.


Eligibility criteria: Inclusion Criteria:

* vitreous haemorrhage
* tractional retinal detachment
* active proliferative diabetic retinopathy.

Exclusion Criteria:

* neovascular glaucoma
* cataract
* combined traction and rhegmatogenous RD

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):785-91. doi: 10.1007/s00417-010-1303-3. Epub 2010 Feb 5.
Clinical trial NCT06219434: Evaluation of a Mindfulness Intervention to Prevent Chemo-brain in Women Preparing for Chemotherapy for Breast Cancer
Official title: Pilot Feasibility Evaluation of a Mindfulness (Mindfulness) Intervention in Women Preparing for Chemotherapy for Breast Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Breast Carcinoma
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
First posted: 2024-01-23
Enrollment: 12
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This clinical trial tests how well a mindfulness intervention helps the prevention of chemotherapy-brain (chemo-brain) in women preparing for chemotherapy for breast cancer. Cognitive dysfunction after chemotherapy has been well-documented. Factors that have been used to document and/or have been correlated with chemo brain include self-report and structural brain changes including volume loss. Mindfulness is a type of meditation practice that can be learned to support well-being and decrease stress. Mindfulness is an approach that helps the person increase their awareness of the present moment without judgement. There are data that mindfulness may increase attention and concentration which may prevent some of the side effects from chemotherapy

Detailed description: PRIMARY OBJECTIVES:

I. Assess the feasibility of an 8-week mindfulness intervention in women preparing for chemotherapy for breast cancer.

II. Evaluate cognitive dysfunction related factors as an exploratory objective: cognitive function, quality of life, inflammatory markers, functional magnetic resonance imaging (fMRI) brain imaging, and a record of mindfulness practice.

OUTLINE:

Patients participate in a mindfulness program composed of topics that include mindfulness of breathing and the body scan, mindful eating, mindful activity, mindfulness in daily life, expanding the field of awareness, and maintaining a flexible mindfulness practice weekly over 2.5 hours for 8 weeks. Patients also undergo blood sample collection and fMRI on the study.

After completion of study intervention, patients are followed up at 3 months.

Eligibility criteria: Inclusion Criteria:

* 18 years or older
* Breast cancer diagnosis preparing to undergo chemotherapy

Exclusion Criteria:

* Under the age of 18
* Cannot provide informed consent

Primary outcomes:
measure: Participation rate
timeFrame: Up to 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Thomas Jefferson University Hopsital
state: Pennsylvania
Study officials:
References:
Clinical trial NCT06701734: Targeted Translocator Protein PET Imaging Evaluate Neuroinflammation of the Chronic Pain Patients
Official title: Targeted Translocator Protein PET Imaging Evaluate Neuroinflammation of the Chronic Pain Patients
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Chroinc Pain
PET
Microglial Activation
Lead sponsor: First Affiliated Hospital of Fujian Medical University
Sponsor class: OTHER
First posted: 2024-11-22
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with chronic pain

Brief summary: Chronic pain is a major public health issue, which seriously affects patients' quality of life. Neuroinflammation is an important mechanism resulting in chronic pain. Translocator protein (TSPO) has served as a marker of microglial activation and neuroinflammation. 18F-DPA714, a tracer targeted TSPO, can be used to evaluate the microglial activation and neuroinflammation in vivo by PET imaging.Recent and increasing studies have found changes in TSPO and its ligands in various chronic pain models. Reversing their expressions has been shown to alleviate chronic pain in these models, illustrating the effects of TSPO and its ligands.The investigators aim to explore the clinical feasibility used 18F-DPA714 PET imaging to monitor microglial cells activation of center nervous system in chronic pain patients. This study might reveal significant neuroinflammatory process in the center nervous system of the chronic pain patients. The results of this study might provide a new biomarker of disease pathological progression and indicates that TSPO-based therapy may become an alternative strategy for treating chronic pain.


Eligibility criteria: Inclusion Criteria:

* chronic pain patients
* Written informed consent was provided by the patients and their family

Exclusion Criteria:

* history of head trauma ， epilepsy， claustrophobia, rheumatic or autoimmune diseases, psychiatric disorders, severe somatic diseases (neurological,cardiovascular, etc.),previous heart or brain surgery, substance abuse, inability to refrain from hypnotics, magnetic implants, pregnancy, lactation

Primary outcomes:
measure: Standardized Uptake Value
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04264234: Management Of Placenta Previa Cases And Determination Of Hospitalization Criteria
Official title: Management Of Placenta Previa Cases And Determination Of Hospitalization Criteria
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Placenta Previa
Keywords: placenta previa
placental invasion anomalies
timing of the birth
Lead sponsor: Ege University
Sponsor class: OTHER
First posted: 2020-02-11
Enrollment: 98
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Placenta previa cases will be followed up at 28th gestational week and evaluated at 32nd week by vaginal ultrasonography and MRI and this follow-up will continue until delivery.
Primary purpose: DIAGNOSTIC

Brief summary: Placenta previa cases are one of the difficult groups of patients to manage in modern obstetrics. When the literature is evaluated extensively, no clear information can be seen especially in terms of hospitalization time. Inpatient follow-up of this patients has negative effects like hospital infections in terms of the patient, workload in terms of health personnel and financial losses in terms of the country's economy. Placenta previa cases are complicated patients in which generalizations cannot be easily performed and they should be monitored at third level hospitals. In addition, care should be personalized considering the many reasons. In this study, placenta previa cases will be followed up at 28th gestational week and evaluated at 32nd week by vaginal ultrasonography and MRI and this follow-up will continue until delivery. Thus, in this study, it was aimed to determine the parameters that would allow systematic personalization of health service in this particular patient group by making risk assessment of placenta previa cases.


Eligibility criteria: Inclusion Criteria:

* Monitoring of placenta previa
* To apply before the 28th week
* To have a low-risk second trimester screening test
* No malformation detected in the anomaly screening

Exclusion Criteria:

* Multiple pregnancies
* Pregnancy complicated with preeclampsia
* Pregnancy complicated by gestational hypertension
* Pregnancy complicated by gestational diabetes mellitus

Primary outcomes:
measure: The number of placental invasion pathologies
timeFrame: 1 day
measure: The number of preterm birth
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: İzmir
country: Turkey
facility: Ege University Hospital
Study officials:
affiliation: Ege University
name: Sabahattin a Arı, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03245034: Assessing the Impact of Acupuncture Therapy on Medical Resident Well-Being: Feasibility and Acceptance
Official title: Assessing the Impact of Acupuncture Therapy on Medical Resident Well-Being: Feasibility and Acceptance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Exhaustion; Syndrome
Keywords: Medical Residents
Well-Being
Stress/Burnout in Medical Residents
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2017-08-10
Enrollment: 12
Sex: ALL
Minimum age (years): 25
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This feasibility study develops methods for larger-scale research, evaluating the acceptability and perceived impact of a group acupuncture and acupressure intervention, as well as suitability of a self-report instrument. During their weekly training program, eleven OB residents at NYU Lutheran Medical Center will receive three sessions of auricular acupuncture therapy. (This resident population was previously anonymously surveyed and all expressed interest in participating in such a study). The Professional Quality of Life Scale (ProQOL) will be administered at 6 time points. A brief survey will also be given to assess participants' acceptance of the intervention as well as applicability of the ProQOL instrument. Additional feasibility-related outcomes include protocol compliance/withdrawals, adverse events, and time taken to complete intervention and surveys.


Eligibility criteria: Inclusion Criteria:

* Enrollment in NYU Lutheran Obstetrics \& Gynecology Residency program

Exclusion Criteria:

* Women currently pregnant or attempting to conceive

Primary outcomes:
measure: Professional Quality of Life (ProQOL)
timeFrame: 4 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York University School of Medicine
state: New York
Study officials:
affiliation: NYU Langone Health
name: Meera Kesavan, MD
role: PRINCIPAL_INVESTIGATOR
References: